Provided by Tiger Trade Technology Pte. Ltd.

Tredegar

7.40
-0.3300-4.27%
Volume:107.13K
Turnover:793.87K
Market Cap:258.34M
PE:7.73
High:7.62
Open:7.62
Low:7.32
Close:7.73
52wk High:10.53
52wk Low:6.25
Shares:34.91M
Float Shares:28.20M
Volume Ratio:1.05
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.9572
EPS(LYR):0.9604
ROE:15.47%
ROA:6.50%
PB:1.13
PE(LYR):7.71

Loading ...

TG Therapeutics: Buy Rating Reaffirmed as Briumvi Schizophrenia Trial Adds Upside Optionality; $70 Price Target Unchanged

TIPRANKS
·
Jul 06

TG Therapeutics initiates Briumvi clinical trial

TIPRANKS
·
Jul 06

Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape

GlobeNewswire
·
Jul 01

TG Therapeutics (TGTX) Gains Momentum As The Fair Value Narrative Turns More Cautious

Simply Wall St.
·
Jun 26

TG Jones backs down from clash with landlords in bid to save stores

cityam
·
Jun 23

TG Therapeutics price target raised to $83 from $57 at Jefferies

TIPRANKS
·
Jun 23

Jefferies Reaffirms Their Buy Rating on TG Therapeutics (TGTX)

TIPRANKS
·
Jun 22

TG Metals Issues 649,386 Unquoted Performance Rights Under Employee Incentive Plan

TIPRANKS
·
Jun 19

TG Therapeutics Stock Rises Thursday: What's Driving The Gains?

Benzinga_recent_news
·
Jun 19

TG-17 Schedules CEO-Led Investor Webinar for June

TIPRANKS
·
Jun 17

TG-17 Restructures Capital and Leadership to Support Growth

TIPRANKS
·
Jun 16

Major Tredegar Insiders Quietly Unload a Chunk of Shares in Near-Identical Trades

TIPRANKS
·
Jun 16

Tredegar 10% owner James T. Gottwald sells 26,298 shares worth $213,783.27

Reuters
·
Jun 16

TG Therapeutics Shareholders Reject Executive Compensation at Meeting

TIPRANKS
·
Jun 13

Major Insider Trio Makes Synchronized Exit Move in Tredegar Stock

TIPRANKS
·
Jun 12

Tredegar 10% owner James T. Gottwald disposes of USD 146,820 in common shares

Reuters
·
Jun 12

Tredegar 10% owner John D. Gottwald sells 18,159 shares for $145,351.53

Reuters
·
Jun 12

A Look At TG Therapeutics (TGTX) Valuation After Fresh BRIUMVI Clinical And Formulation Milestones

Simply Wall St.
·
Jun 10

TG Therapeutics: Buy Rating Reiterated on Briumvi Expansion Strategy, $70 Price Target Unchanged

TIPRANKS
·
Jun 09

Major Insider Trio Quietly Trims Tredegar Holdings in Synchronized Stock Moves

TIPRANKS
·
Jun 09